- Home
- TTNP vs SLXN Comparison
TTNP vs SLXN Comparison
Compare TTNP & SLXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TTNP
- SLXN
- Stock Information
- Founded
- TTNP 1991
- SLXN 2008
- Country
- TTNP United States
- SLXN Israel
- Employees
- TTNP N/A
- SLXN N/A
- Industry
- TTNP Biotechnology: Biological Products (No Diagnostic Substances)
- SLXN
- Sector
- TTNP Health Care
- SLXN
- Exchange
- TTNP Nasdaq
- SLXN NYSE
- Market Cap
- TTNP 3.7M
- SLXN 3.0M
- IPO Year
- TTNP 1996
- SLXN N/A
- Fundamental
- Price
- TTNP $3.81
- SLXN $0.21
- Analyst Decision
- TTNP
- SLXN Strong Buy
- Analyst Count
- TTNP 0
- SLXN 1
- Target Price
- TTNP N/A
- SLXN $1.00
- AVG Volume (30 Days)
- TTNP 8.5K
- SLXN 1.5M
- Earning Date
- TTNP 11-29-2024
- SLXN 11-14-2024
- Dividend Yield
- TTNP N/A
- SLXN N/A
- EPS Growth
- TTNP N/A
- SLXN N/A
- EPS
- TTNP N/A
- SLXN N/A
- Revenue
- TTNP $3,000.00
- SLXN N/A
- Revenue This Year
- TTNP N/A
- SLXN N/A
- Revenue Next Year
- TTNP N/A
- SLXN N/A
- P/E Ratio
- TTNP N/A
- SLXN N/A
- Revenue Growth
- TTNP N/A
- SLXN N/A
- 52 Week Low
- TTNP $3.57
- SLXN $0.21
- 52 Week High
- TTNP $14.80
- SLXN $13.56
- Technical
- Relative Strength Index (RSI)
- TTNP 34.23
- SLXN N/A
- Support Level
- TTNP $3.77
- SLXN N/A
- Resistance Level
- TTNP $4.66
- SLXN N/A
- Average True Range (ATR)
- TTNP 0.28
- SLXN 0.00
- MACD
- TTNP 0.04
- SLXN 0.00
- Stochastic Oscillator
- TTNP 3.93
- SLXN 0.00
About TTNP Titan Pharmaceuticals Inc.
Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.
About SLXN BIOMOTION SCIENCES
Silexion Therapeutics Corp is a developmental-stage company dedicated to the development of treatments for pancreatic cancer. The company is focused on enhancing its first-generation product (LODERTM ) to develop a newly formulated product to improve the clinical efficacy against pancreatic cancer.